Anthos Therapeutics Inc.
- Address
- 1 Health Plaza
Sponsor Overview
Specializations
Atrial Fibrillation
Anthos Therapeutics Inc. is active in clinical research for atrial fibrillation, with studies centered on reducing the risk of ischemic stroke and systemic embolism in patients who are not suitable candidates for standard oral anticoagulation.
- Stroke prevention
- Systemic embolism
- Anticoagulation unsuitability
The sponsor’s interest in this area reflects a focus on thromboembolic risk management in patients with cardiac rhythm disorders.
Venous Thromboembolism
The company’s research portfolio includes venous thromboembolism treatment and recurrence prevention, with attention to patients following a recent VTE event and to outcomes related to bleeding risk during anticoagulant therapy.
- VTE recurrence prevention
- Bleeding risk
- Anticoagulant therapy
These studies place emphasis on balancing protection from clot recurrence with safety in long-term thrombotic disease management.
Cancer-Associated Thrombosis
Anthos Therapeutics also funds research in cancer-associated thrombosis, particularly venous thromboembolism in patients with gastrointestinal cancer and genitourinary cancer, where clot prevention and treatment remain clinically challenging.
- Gastrointestinal cancer
- Genitourinary cancer
- Oncology-related VTE
The sponsor’s activity in this domain is directed toward thrombotic complications arising in oncology populations.
Factor XIa Inhibition
The research program is built around abelacimab, a Factor XIa inhibitor studied across cardiovascular and thrombotic conditions, including atrial fibrillation and venous thromboembolism.
- Factor XIa
- Abelacimab
- Thrombosis prevention
This therapeutic focus connects anticoagulation research with efforts to address clot-related disease in both cardiac and cancer settings.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of the Safety and Tolerability of Abelacimab Versus Rivaroxaban in Patients with Atrial Fibrillation: A Randomized Controlled Trial |  Czechia Hungary Poland | Not Recruiting |
| Phase 3 Multicenter Randomized Study of Abelacimab vs. Apixaban on VTE Recurrence and Bleeding in Cancer-Associated Venous Thromboembolism |  Austria Czechia France Germany Hungary Ireland Italy Latvia Norway Spain Sweden The Netherlands | Not Recruiting |
| Phase 3 Multicenter Study on Abelacimab vs. Dalteparin for VTE Recurrence and Bleeding in GI/GU Cancer-Associated VTE Patients | Austria Czechia France Germany Hungary Ireland Italy Latvia Norway Spain Sweden The Netherlands | Not Recruiting |
| Phase 3 Study on Abelacimab Efficacy and Safety in High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation |  Bulgaria Croatia Czechia Estonia Finland Germany Greece Hungary Italy Latvia Poland Romania Slovakia Spain Sweden | Recruiting |
Data & Insights
This sponsor works with 4 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 319 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases4 trials359 other sponsors
Partnered Research Centres
319 centres- Address
- ul. Partyzantow 39/64, 81-423 Gdynia
- Address
- Ul. Aleje Raclawickie 23, 20-049 Lublin
- Address
- Ul. 1 Maja 323, 41-710 Ruda Śląska
- Address
- Lundagatan 23 Nb, Hogalid, 117 27 Stockholm
- Address
- Sykehusveien 25, 1474 Lorenskog
- Address
- Albert Schweitzerplaats 25, 3318 AT Dordrecht
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Anthos Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.